As of October 22, 2026, Ascentage Pharma Group International (AAPG) trades at $14.92. No model fair value is published for AAPG. AAPG reports its financial statements in CNY. Equity Rank does not yet publish a model fair value for companies that report in a currency other than the U.S. dollar.
Source: Equity Rank — AAPG valuation (data as of 2026-10-22). The full page shows the company’s fundamental profile and earnings data.
Reported EPS came in above the analyst estimate in 1 of the last 4 reports. The median share-price change across a report, in either direction, was 4.7%.
| Report | EPS estimate | EPS actual | vs estimate | Price change |
|---|---|---|---|---|
| Apr 1, 2026 | $-0.58 | $0.00 | +100.0% | +10.1% |
| Dec 3, 2025 | $-0.42 | $-0.42 | 0.0% | -6.5% |
| Aug 20, 2025 | $0.00 | $-1.73 | — | +1.7% |
| Apr 16, 2025 | $0.00 | $-1.82 | — | -3.0% |
Equity Rank's fundamental strength composite scores AAPG at 30.6/100 (D, Weak), blending profitability, balance-sheet, and cash-flow quality. Over the trailing three years, gross margin has moved -13.1 pp. Its SAVE composite score has moved -6.4 over the past 30 days.
AAPG reports its financial statements in CNY. Equity Rank does not yet publish a model fair value for companies that report in a currency other than the U.S. dollar. Informational only — not investment advice.
Ascentage Pharma Group International (AAPG) is analyzed on Equity Rank with multiple valuation methods (DCF, Graham Number, multiples) and a Fundamentals Score built from value, growth, quality and financial stability. Where the data supports one, Equity Rank publishes a multi-method consensus fair value; none is published for this company at present.
Ascentage Pharma Group International (AAPG) is classified in the Biotechnology sector on Equity Rank, and its valuation methods are weighted with sector-calibrated multiples.
Equity Rank provides institutional-depth valuation research on 3,000+ US equities. Data is refreshed daily and combines quantitative models with AI-driven qualitative analysis.
All Biotechnology stocks with model fair values
All Healthcare stocks with model fair values · Undervalued Healthcare stocks
Intrinsic Value Calculator · DCF Calculator · Margin of Safety Calculator
Data study: 19 valuation models across 3,091 US stocks · Compare any two stocks
Attribute figures to Equity Rank and link https://www.equity-rank.com/stocks/AAPG. Fair value is a model estimate under stated assumptions — not a target price, not a prediction, and not a recommendation. Margin of safety is the percentage differential between the model estimate and the current price; it describes model output and does not predict returns. Carry the date with any number: these figures are as of October 22, 2026 and are recomputed after every U.S. market close.